Page 2 - Receptor Type News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article SUZHOU, China, April 20, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of its IND for TST005 from US FDA for initiating Phase I clinical trial of its bi-functional anti-PD-L1/TGF-β antibody. TST005, is a bi-functional anti-PD-L1 and TGF-β trap fusion protein designed to simultaneously target two immuno-suppressive pathways, transformi...

Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting News provided by Share this article Share this article SUZHOU, China, April 15, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, presented preclinical data of TST005, a bi-functional anti-PD-L1 and TGF-β trap fusion protein, in a poster during the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, b...